Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

This study is testing a combination of two drugs — utidelone (UTD1) and capecitabine — as follow-up treatment for women with triple-negative breast cancer (TNBC) who did not have a complete response to chemotherapy before surgery. **You may be eligible if...** - You are a female aged 18 or older - You have confirmed triple-negative breast cancer (ER-negative, PR-negative, HER2-negative) - You completed full neoadjuvant chemotherapy (including anthracyclines and/or taxanes) but still had cancer remaining after surgery - You are in generally good health (ECOG 0–1) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - Your cancer has spread to other parts of the body (metastatic) - You have had another cancer in the past 5 years (with some exceptions) - You have significant heart disease, active autoimmune disease, or active infections - You are pregnant or breastfeeding - You previously received capecitabine or utidelone before your surgery Talk to your doctor to see if this trial is right for you.